Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries

cnbc.com · 2026-09-08

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

TickrTrends take: Amgen operates in the Healthcare sector alongside competitors like Lilly, and broader pressure on drug stocks could test whether Amgen's current valuation premium is justified by its pipeline and commercial performance. TickrTrends' overvalued assessment suggests the market may be pricing in optimistic expectations that sector headwinds could challenge. Investors focused on valuation should monitor whether weakness among peer companies signals deteriorating fundamentals in the pharmaceutical space or presents a repricing opportunity.

Read the full story at cnbc.com →